Navigation Links
Ariosa Diagnostics Selected as NIPT Service Provider in Majority of California Comprehensive Prenatal Diagnosis Centers Throughout the State

SAN JOSE, Calif., Nov. 1, 2013 /PRNewswire/ -- Ariosa Diagnostics, Inc., maker of the Harmony™ Prenatal Test, announced today that it has been selected as a key provider of non-invasive prenatal testing (NIPT) services in the majority of the 28 comprehensive Prenatal Diagnosis Centers (PDC) throughout the State of California. The Harmony test, which is the most widely used NIPT globally, is being offered to pregnant women as part of the California Prenatal Screening Program at no additional cost, subject to the program requirements.


Currently, the California Prenatal Screening Program offers traditional serum and neural tube defect screening to the general population of pregnant women. Patients found to be screen positive for possible chromosome conditions (such as Down syndrome or trisomy 18), or have an increased nuchal translucency measurement, are referred for other services that include genetic counseling, ultrasound, amniocentesis and chorionic villus sampling (CVS). Given its increased sensitivity and specificity, the State has now introduced NIPT as another option in evaluating patients who have an increased risk for chromosome conditions based on their serum screening results. 

The Harmony test has the most published data of any NIPT available for pregnant women of any age, fetal gestational age and risk-profile. Published in over 13 peer-reviewed studies, involving thousands of patients, the test has demonstrated greater than 99% accuracy for Down syndrome with a less than 0.1% false positive rate, thereby diminishing the potential for women to unnecessarily proceed to invasive diagnostic procedures that may result in pregnancy complications in an otherwise normal fetus.  

About Ariosa Diagnostics

Ariosa Diagnostics, Inc. is a molecular diagnostics company committed to innovating together to improve patient care. The flagship product, the HarmonyTM Prenatal Test, is a safe, highly accurate and affordable prenatal test for maternal and fetal health. Led by an experienced team, Ariosa is using its proprietary technology to perform a directed analysis of cell-free DNA in blood. The HarmonyTM Prenatal Test equips pregnant women and their healthcare providers with reliable information to make decisions regarding their health, without creating unnecessary stress or anxiety.

The company began operations in 2010 and is headquartered in San Jose, Calif. For more information, visit Follow us on Twitter @HarmonyPrenatal and on Facebook at Harmony Prenatal for Healthy Pregnancy.

Jen Bruursema

SOURCE Ariosa Diagnostics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Ariosa Diagnostics Wins Summary Judgment Against Sequenom on Cell-free DNA Patent
2. Ariosa Diagnostics Introduces Y-Chromosome Analysis Test Option
3. Ariosa Diagnostics to Present and Exhibit at the 16th International Conference on Prenatal Diagnosis and Therapy
4. PDI, Inc. Appoints Molecular Diagnostics Leader to Board of Directors
5. Does Your Business Have the Tools to Compete in the Worlds Largest Diagnostics Markets?
6. Exagen Diagnostics Appoints New Board Member
7. Frost & Sullivan Unveils Future Opportunities for the Tissue Diagnostics Market
8. DNA Diagnostics Center (DDC), One of the Worlds Largest DNA Testing Companies, Increases the Identification Power of its DNA Tests by More Than 500%
9. Ampio Pharmaceuticals subsidiary Luoxis Diagnostics announces positive summary data from study of traumatic brain injury patients and issuance of companys third US patent for its oxidation-reduction potential diagnostic platform
10. Life Technologies and Advanced Cell Diagnostics Sign Global Distribution Agreement
11. Increasing Public Health Awareness Intensifies Global Uptake of Autoimmune Disease Diagnostics
Post Your Comments:
(Date:11/26/2015)... Research and Markets ( ) has announced ... Outlook to 2019 - Rise in Cardiac Disorders and Growing ... to their offering. Boston ... scientific and others. --> The market ... Boston scientific and others. ...
(Date:11/26/2015)... , Nov. 26, 2015 Research and ... of the "2016 Future Horizons and Growth ... Market: Supplier Shares, Country Segment Forecasts, Competitive Intelligence, ... --> --> ... of the Japanese therapeutic drug monitoring market, including ...
(Date:11/26/2015)... DUBLIN , November 26, 2015 ... has announced the addition of the  ... in the Global Cell Surface Testing ... Opportunities" report to their offering.  ... the addition of the  "2016 Future ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... November 30, 2015 , ... The successful filing of an Investigational ... it is so important to this key industry segment, Regis Technologies has decided to ... on December 4th at 11am EST. , Federal law does not allow new drugs ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... of critical importance to the medical schools of the future. To reach an ... suite at the 2015 ChangeMedEd conference in Chicago, organized by the American Medical ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... their strategic partnership at the Radiological Society of North America (RSNA) 2015 ... global providers of cutting-edge dictation and speech-enabled documentation software, announced their partnership ...
(Date:11/30/2015)... Wylie, TX (PRWEB) , ... November 30, 2015 , ... Bayco Products, Inc today announced ... only $11.95 each. Available in a choice of three different colors; red ( NSP-1632 ), ... can each run up to 18 hours in constant-on mode, or 27 hours in blinking ...
(Date:11/29/2015)... FL (PRWEB) , ... November 30, 2015 , ... The Cyber Monday deal is a ... It is the right time to get gifts for the skin care lover in your ... top filled with serums . This year, the 3 serums are staples: Collagen, Retinol and ...
Breaking Medicine News(10 mins):